Drug News

Added 7 hours ago Drug news

FDA approves prescription digital therapeutic, reSET-O for patients with opioid use disorder. Sandoz.

Sandoz Inc., a division of Novartis, and Pear Therapeutics, Inc., the leader in prescription digital therapeutics, announced that the FDA...

Added 7 hours ago Drug news

Phase III study of Liletta for contraception published in American Journal of Obstetrics & Gynecology.- Medicines360/Allergan.

Medicines360/Allergan announced newly published data finding that Liletta (levonorgestrel releasing intrauterine system) is highly efficacious in preventing pregnancy over five...

Added 7 hours ago Drug news

New data demonstrates IV meloxicam’s effect on platelet function.- Recro Pharma

Recro Pharma, Inc. announced a poster presentation highlighting intravenous (IV) meloxicam’s effect on platelet function at the 72nd PostGraduate Assembly...

Added 7 hours ago Drug news

Interim analysis of long-term study shows Zydis safe for migraine.- Biohaven Pharmaceutical.

Biohaven Pharmaceutical announced initial positive results from its ongoing long-term, open-label safety study of Zydis (rimegepant), for the acute treatment...

Added 7 hours ago Drug news

Real-world data supports usage of Oncotype DX Breast Recurrence Score test in breast cancer.- Genomic Health.

Long-term outcomes data from a large population-based study further support the utility of the Oncotype DX Breast Recurrence Score test,...

Added 1 day ago Drug news

Positive phase III results for F 627 in neutropenia in breast cancer.- Generon.

Generon BioMed announced positive results from a placebo-controlled trial with F 627 (benegrastim), a recombinant human Granulocyte Colony Stimulating Factor...

Added 2 days ago Drug news

Data analysis of MONALEESA trials shows efficacy and tolerability of Kisqali in HR+/HER2- advanced breast cancer in patients with difficult-to-treat visceral disease.-Novartis

Novartis announced data from subgroup analyses of the three pivotal Phase III MONALEESA trials showing that Kisqali (ribociclib) plus endocrine...

Added 2 days ago Drug news

Positive Phase III trial for Zydis orally dissolving tablet to treat acute migraine.- Biohaven,

Biohaven Pharmaceutical Holding Company Ltd.announced positive topline results from a randomized, controlled Phase III clinical trial (BHV 3000-303 or Study...

Added 3 days ago Drug news

NICE now allows Yescarta in specific cases for large B-cell lymphoma.- Gilead/Kite.

The National Institute for Health and Care Excellence announced that Yescarta (axicabtagene ciloleucel), from Gilead Sciences/Kite Pharma, will be available...

Added 3 days ago Drug news

Imfinzi + tremelimumab combination does not meet overall survival endpoint in Phase III EAGLE trial for head & neck cancer-AstraZeneca

AstraZeneca and MedImmune, its global biologics research and development arm, announced overall survival (OS) results for the Phase III EAGLE...

Search all news articles